Mithra’s General Meeting Of Shareholders Approves the Renewal of
its Board of Directors
Liege, Belgium, 25 MAY 2023 – 5:45 CEST –
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s
Health, today announces that at its Annual General Meeting, held
today all agenda items put to vote were approved, including the
appointment of Directors for a two-year mandate. The Board of
Directors is now made up of 7 members with varied backgrounds
spanning both the financial and pharmaceutical sectors, bringing
extensive expertise to Mithra covering all aspects of
pharmaceutical development.
The Board will include four new Directors,
including:
Ribono SRL, Mr. Sidney Bens (Independent
Director)
Sidney is a seasoned financial executive, with
over 35 years’ experience. He spent most of his career at Atenor,
an international real estate development company listed on
Euronext, where he served as Chief Financial Officer. Prior
to this he worked in banking, as Senior Corporate Banker at Paribas
Bank Belgium (now Belfius) and in Retail and SMC banking at BBL
(now ING). Sidney holds a Masters degree in Finance, Accounting and
Trade from Lucien Cooremans Institute, Belgium and a Postgraduate
in Finance from KU Leuven, Belgium, (see resume).
Mrs. Igne Beernaert (Independent
Director)
Igne is an experienced financial services
professional, specializing in audit, corporate finance, internal
controls, tax, management and M&A. She is the founder of
Bedrijfsrevisor Beernaert, a financial advisory firm that provides
audit, M&A and strategic financial consulting for growing
companies, where she served as company auditor for the last 27
years. Prior to this, she founded bb3 Revisoren, another financial
advisory firm. Igne holds a Masters degree in Applied Economics
from KU Leuven, Belgium and a postgraduate degree in liability and
insurance law from the University of Antwerp, (see resume).
Life Science Strategy Consulting SRL, Mr.
Christian Homsy (Independent Director)
Christian is a leading life sciences executive
with over 30 years’ industry experience. Most recently he founded
and served as interim Chief Executive Officer and Board Member of
biotechnology company Capstan Therapeutics. He was also founder,
Chief Executive Officer and Board Member of Celyad SA for 15 years.
He spent a large part of his career at Guidant Corporation (part of
Boston Scientific and Abbott Labs) in a number of senior roles.
Christian gained his Medical Doctorate at the University of
Louvain, Belgium and his MBA at IMD Business School, Lausanne,
Switzerland, (see resume).
Gaudeto SRL, Mr. Jacques Galloy (Independent
Director)
Jacques has over 25 years of business leadership
experience including private and public equity capital markets,
focusing on digital imaging, medical technology, digital media and
digital transition. He is currently the founder and managing
partner of Guadeto SPRL, an investment consultancy firm advising
small to mid-size media, health technology and digital transition
companies. He is a current investor in 7 companies, entrepreneur in
5 businesses and charities, and has over 10 board mandates. He also
has 12 years’ experience as Board member and CFO of EVS Broadcast
Equipment SA, a worldwide leader in TV Technology niches and a top
30 Belgian listed company. Jacques holds a Masters in Commercial
Engineering from Ulg-HEC Liège, Belgium, (see resume).
Christian Moretti, Chairman of the Board,
commented: « It is fantastic to welcome such established and
experienced professionals to the Mithra Board of Directors. Their
collective knowledge spanning both the financial and life sciences
sectors will be invaluable to the Company as we continue the
commercialization of our lead product, Estelle and develop our
exciting and innovative pipeline of products to address key unmet
need. »
The General Meeting also renewed the mandates
of:
Selva Luxembourg SA, Mr. Christian Moretti
(Chairman and Non-Executive Director)
Christian is a seasoned financial executive who
spent over 10 years in banking before founding the industrial
holding Dynaction listed on the Paris stock exchange. He then
focused on the development of one of the holding's subsidiaries,
PCAS Biosolution, which he managed as CEO for 13 years and enabled
it to become the European leader in the chemistry of complex
molecules, employing more than 1,000 people worldwide. Christian
holds a Masters in Marketing and Finance from HEC School of
Management, Paris and a Masters of Business Administration from
Columbia Business School, (see resume).
Alius Modi SRL, Ms. Valérie
Gordenne (Non-Executive Director)
Valérie has over 20 years of experience in
pharmaceutical Research & Development with extensive leadership
experience in full drug development across a range of therapeutic
areas in particular in women's health (CSO Mithra, CEO Novalon,
General Manager Odyssea). Through the management of various
functions and activities, she has developed a deep operational and
strategic knowledge in drug development. She is currently Chief
Scientific Officer at Auxin Surgery, CEO of the start-up Odix and
an advisor in regulatory affairs. She has a Masters in
Pharmaceutical Science, University Of Liege, Belgium and a Masters
in Industrial Pharmacy from Inter-University, Belgium, (see
resume).
Eva Consulting SRL, Prof. Jean-Michel
Foidart (Executive Director)
Co-founder of Mithra, Jean-Michel is a trained
doctor specializing in Obstetrics and Gynecology and is the author
of more than 1300 publications on women’s health and experimental
oncology. He is a member of many national and international
scientific committees and is currently a Board member of the
International Society of Gynecological Endocrinology. Jean-Michiel
holds the Francqui Chair, Doctor Honoris Causa of the Pierre and
Marie Curie University of Paris and the Paul Sabatier University of
Toulouse. Professor Extraordinary, Honorary of the ULg and
Perpetual Secretary of the Royal Academy of Medicine of Belgium.
Professor Foidart graduated in Gynecology from the University of
Liège and also obtained a PhD in cell biology and biochemistry,
before directing its Department of Gynecology-Obstetrics, (see
resume).
********
For more information, please contact:
Investor relations :
https://www.mithra.com/
About Estelle®
Developed by Mithra, Estelle® is a novel patent
protected combined oral contraceptive pill containing 3 mg
drospirenone (DRSP) and 15 mg estetrol (E4). E4 is a naturally
produced estrogen during pregnancy, which can now be made from a
plant source. In two phase 3 clinical studies conducted in 3,725
women, Estelle® was shown to be both safe and effective and met its
primary efficacy endpoint of pregnancy prevention. It also
delivered excellent results on a variety of secondary endpoints
that demonstrated outstanding cycle control, bleeding control,
safety, and tolerability. Mithra has signed 15 licensing deals for
Estelle® with a number of leading women’s health companies covering
more than 100 countries in the world.
The product is marketed in Belgium by Gedeon
Richter under the brand name DROVELIS® and by Ceres Pharma
under the brand name -LYDISILKA®.
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech
company dedicated to transforming Women’s Health by offering new
choices through innovation, with a particular focus on
contraception and menopause. Mithra’s goal is to develop products
offering better efficacy, safety and convenience, meeting women’s
needs throughout their life span. Mithra explores the potential of
the unique native estrogen estetrol in a wide range of applications
in women health and beyond. After having successfully launched the
first estetrol-based product in 2021, the contraceptive pill
Estelle®, Mithra is now focusing on its second product Donesta®,
the next-generation hormone therapy. Mithra also offers partners a
complete spectrum of solutions from early drug development,
clinical batches and commercial manufacturing of complex polymeric
products (vaginal ring, implants) and complex liquid injectables
and biologicals (vials, pre-filled syringes or cartridges) at its
technological platform Mithra CDMO. Active in more than 100
countries around the world, Mithra has an approximate headcount of
230 staff members and is headquartered in Liège, Belgium.
www.mithra.com
ESTELLE®, DONESTA®, LYDISILKA are registered
trademarks of Mithra Pharmaceuticals or one of its affiliate
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
- 2023-05-XX_Mithra_Press-release_Board-Updates_FR- Final
Mithra Pharmaceuticals (EU:MITRA)
過去 株価チャート
から 12 2024 まで 1 2025
Mithra Pharmaceuticals (EU:MITRA)
過去 株価チャート
から 1 2024 まで 1 2025